Peli BioThermal expands ‘deep frozen’ range ahead of Covid-19 vaccine
20 / 11 / 2020
Pharma container firm Peli BioThermal has expanded its ‘deep frozen’ product range to include solutions that can hold pharma products from -80 degrees Celsius to -20 degrees Celsius.
Peli BioThermal said its deep frozen solutions can help to maintain supply chains as pharma companies and the air cargo industry prepare to bring Covid-19 vaccines to the market.
Its deep frozen products use phase change material and dry ice systems to provide frozen payload protection for up to 144 hours.
In addition, payload capacities for its deep frozen products range from 1 to 96 litres for parcel shippers and 371 to 1,686 litres for pallet shippers.
The company’s Crēdo Cube solution, which previously maintained temperatures between 20 degrees Celsius and -50 degrees Celsius, has been updated to cover temperatures down to -80 degrees Celsius.
The company said it also offers deep frozen options with its other product lines: CoolGuard, Advance, CoolPal Flex, Sherpa Systems, Crēdo Xtreme and Crēdo Cargo.
“These lines include parcel and pallet sizes, as well as offering both single use and reusable temperature controlled shippers,” the company said.
“Many of these expanded temperature ranges are also available through the Crēdo™ on Demand rental program.”
Greg Wheatley, vice president of worldwide new product development and engineering at Peli BioThermal, commented: “We know that pharmaceutical companies are in all phases of the development process for vaccines and therapeutics and working tirelessly to bring safe and effective drug products to market quickly.
“Our engineering team matched this urgency to ensure they have the correct temperature controlled packaging to meet them where they’re at in drug development for the pandemic recovery, from discovery to distribution.”